Apolipoprotein B: A predictor of inflammatory status in postmenopausal overweight and obese women

Diabetologia

Volumn 49, Issue 7, 2006, Pages 1637-1646

  Faraj, M ^a   Messier, L ^a   Bastard, J P ^b,c   Tardif, A ^a   Godbout, A ^a   Prud'homme, D ^d   Rabasa Lhoret, R ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSERM   (France)

^c HÔPITAL TENON   (France)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Apolipoprotein B; CHD risk factors; Cholesterol; CRP; Inflammatory markers; Lipoproteins

Indexed keywords

ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OROSOMUCOID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABDOMEN; ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; EXAMINATION; FEMALE; HEALTH STATUS; HUMAN; HYPOLIPOPROTEINEMIA; HYPOTHESIS; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCIENCE; SENSITIVITY ANALYSIS; SOLUBILITY;

AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; MIDDLE AGED; OBESITY; OVERWEIGHT; POSTMENOPAUSE; RISK FACTORS;

EID: 33744920293     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0259-7     Document Type: Article

References (40)

1. Bassuk SS, Rifai N, Ridker PM (2004) High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 29:439-493
2. Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600
3. Vasan RS, Sullivan LM, Roubenoff R et al (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107:1486-1491
4. Engstrom G, Stavenow L, Hedblad B et al (2003) Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 52:442-447
5. Engstrom G, Hedblad B, Stavenow L et al (2004) Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler Thromb Vasc Biol 24:1498-1502
6. Schmidt MI, Duncan BB, Sharrett AR et al (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-1652
7. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334
8. Fan J, Watanabe T (2003) Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 10:63-71
9. Kofler S, Nickel T, Weis M (2005) Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (London) 108:205-213
10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565
11. Schritt A, Blankenberg S, Bickel C et al (2005) Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. Int J Cardiol 102:477-485
12. Albert MA, Glynn RJ, Ridker PM (2003) Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108:161-165
13. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM (2002) Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22:1668-1673
14. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE investigators (2001) Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286:64-70
15. Carmena R, Duriez P, Fruchart JC (2004) Atherogenic lipoprotein particles in atherosclerosis. Circulation 109 (Suppl):III2-III7
16. Gorodeski GI (2002) Update on cardiovascular disease in postmenopausal women. Best Practice. Res Clin Obstet Gynaecol 16:329-355
17. Sniderman AD, Scantlebury T, Cianflone K (2001) Hypertriglyceridemia hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:447-459
18. Schectman G, Patsches M, Sasse EA (1996) Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin Chem 42:732-737
19. Genest J, Frohlich J, Fodor G, McPherson R (2003) Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 169:921-924
20. Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44:6-11
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
22. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
23. Karelis AD, Faraj M, Bastard JP et al (2005) The metabolically healthy, but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 90:4145-4150
24. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 57:289-300
25. Pagana KD, Pagana TJ (1997) Diagnostic and laboratory test reference. Mosby-Year Book, St Louis
26. Ginsberg HN (1998) Lipoprotein physiology. Endocrinol Metab Clin North Am 27:503-519
27. Van Gaal L, Zhang A, Steijaert MM, De Leeuw IH (1995) Human obesity: from lipid abnormalities to lipid oxidation. Int J Obesity Rel Metab Dis 19:S21-S26
28. Williams K, Sniderman AD, Sattar N, D'Agostino R Jr, Wagenknecht LE, Haffner SM (2003) Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 108:2312-2316
29. Sniderman AD, Cianflone K, Frayn K (1997) The pathogenetic role of impaired fatty acid trapping by adipocytes in generating the pleiotropic features of hyperapoB. Diabetologia 40:S152-S154
30. Young V, Toborek M, Yang F, McClain C, Hennig B (1998) Effect of linoleic acid on endothelial cell inflammatory mediators. Metabolism 47:566-572
31. Lopez-Garcia E, Schulze MB, Meigs JB et al (2005) Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 135:562-566
32. Han SN, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN (2002) Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res 43:445-452
33. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (1999) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209-214
34. Sun H, Koike T, Ichikawa T et al (2005) C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 167:1139-1148
35. Tsiotra PC, Tsiogos C, Partis SA (2001) TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obesity Rel Metab Dis 25:1018-1026
36. Grossi SG (2001) Treatment of periodontal disease and control of diabetes: an assessment of the evidence and need for future research. Ann Periodontol 6:138-145
37. Barzilay JI, Abraham L, Heckbert SR et al (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 50:2384-2389
38. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137
39. Harano Y, Kageyama A, Nakao K et al (1996) Quantitative and qualitative derangement of apolipoprotein B-containing lipoproteins as a risk factor for diabetic macroangiopathy in nonobese NIDDM subjects. Diabetes 45:S31-S34
40. Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-850